期刊
DIAGNOSTICS
卷 11, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics11010015
关键词
cytology; nCounter; NSCLC
The study utilized the multiplex technology nCounter to detect ALK, ROS1, RET, and MET Delta ex14 in cytological specimens and biopsies, with higher evaluability and housekeeping gene expression in biopsies. Positive cases of ALK, MET Delta ex14, and high MET expression were detected in cytological samples.
The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (MET Delta ex14) allows for the selection of specific kinase inhibitor treatment in patients with non-small cell lung cancer (NSCLC). Multiplex technologies are recommended in this setting. We used nCounter, a multiplexed technology based on RNA hybridization, to detect ALK, ROS1, RET, and MET Delta ex14 in RNA purified from cytological specimens (n = 16) and biopsies (n = 132). Twelve of the 16 cytological samples (75.0%) were evaluable by nCounter compared to 120 out of 132 (90.9%) biopsies. The geometrical mean (geomean) of the housekeeping genes of the nCounter panel, but not the total amount of RNA purified, was significantly higher in biopsies vs. cytological samples. Among cytological samples, we detected ALK (n = 3), MET Delta ex14 (n = 1) and very high MET expression (n = 1) positive cases. The patient with MET Delta ex14 had a partial response to tepotinib, one of the patients with ALK fusions was treated with crizotinib with a complete response. Cell blocks and cytological extensions can be successfully used for the detection of fusions and splicing variants using RNA-based methods such as nCounter.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据